Praxis Precision Medicines, Inc. (PRAX)

Market Cap	778.30M
Revenue (ttm)	8.55M
Net Income (ttm)	-182.82M
Shares Out	20.16M
EPS (ttm)	-10.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,197,393
Open	39.95
Previous Close	65.03
Day's Range	37.60 - 42.55
52-Week Range	33.01 - 91.83
Beta	2.77
Analysts	Strong Buy
Price Target	132.80 (+244.04%)
Earnings Date	Feb 28, 2025

About PRAX

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 16, 2020
• Employees: 82
• Stock Exchange: NASDAQ
• Ticker Symbol: PRAX
• Website: https://praxismedicines.com

Financial Performance

In 2024, PRAX's revenue was $8.55 million, an increase of 249.53% compared to the previous year's $2.45 million. Losses were -$182.82 million, 48.3% more than in 2023.

Analyst Forecast

According to 10 analysts, the average rating for PRAX stock is "Strong Buy." The 12-month stock price forecast is $132.8, which is an increase of 244.04% from the latest price.

Price Target

$132.8

(244.04% upside)

Analyst Consensus: Strong Buy